AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Why Did Ekso Bionics Plunge 31.35%? Revenue Drops 58%
Generated by AI AgentAinvest Pre-Market Radar
Tuesday, Jul 29, 2025 5:31 am ET1min read
Aime SummaryOn July 29, 2025,
experienced a significant drop of 31.35% in pre-market trading, reflecting a substantial decline in investor confidence.Ekso Bionics reported a significant decline in revenue for the second quarter of 2025, falling to $2.1 million from $5.0 million in the same period of 2024. This represents a 58% year-over-year decrease, primarily attributed to delays in multi-device Enterprise Health sales. The company's earnings per share loss for the quarter was $(1.24), which was narrower than expected.
Despite the overall revenue decline, Ekso Bionics saw growth in its Personal Health product revenues, which increased by more than 50% for the first half of 2025. This growth was driven by the company's AI-powered rehabilitation push, which has been a key focus area for Ekso Bionics.
The company's stock saw a 6.02% decline during the day, followed by a 7.05% rise in aftermarket trading, indicating a mixed reaction from investors to the financial results and the company's strategic initiatives.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Dakota Gold DC shares plummeted 6.90% as mining stocks selloff follows sharp gold silver price declines
Dec.30 2025
Integra Resources shares plunge 9.58% on Dec. 30 2025 as project delays regulatory uncertainties spook investors
Dec.30 2025
AXT shares fell 5.07% in pre-market trading on Dec. 30 2025 amid sector pressures and speculative positioning adjustments.
Dec.30 2025
Autozi Internet shares surged 8.76% on strategic AI pivot and regulatory progress
Dec.30 2025
ProKidney shares plunged 13.04% due to regulatory scrutiny and operational concerns
Dec.30 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet